Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1659

1.

A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.

Kirbach S, Simpson K, Nietert PJ, Mintzer J.

Clin Drug Investig. 2008;28(5):291-303.

PMID:
18407715
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.
4.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
5.

The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.

Ballard C, Waite J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476. Review.

PMID:
16437455
6.
7.

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group.

N Engl J Med. 2006 Oct 12;355(15):1525-38.

8.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
9.
10.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.

Pharmacoeconomics. 2005;23 Suppl 1:35-47.

PMID:
16416760
11.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

13.

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.

Jönsson L.

Am J Geriatr Pharmacother. 2005 Jun;3(2):77-86.

PMID:
16129384
14.

The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.

Clark WS, Street JS, Feldman PD, Breier A.

J Clin Psychiatry. 2001 Jan;62(1):34-40.

PMID:
11235926
15.

A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.

Beard SM, Maciver F, Clouth J, Rüther E.

Eur J Health Econ. 2006 Sep;7(3):165-72.

PMID:
16896764
16.

Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.

Taylor DM, Wright T, Libretto SE; Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.

J Clin Psychiatry. 2003 May;64(5):589-97.

PMID:
12755664
17.

A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.

Cooper D, Moisan J, Abdous B, Grégoire JP.

Can J Clin Pharmacol. 2008 Fall;15(3):e385-97. Epub 2008 Oct 24.

18.

Antipsychotic treatment of psychosis and agitation in the elderly.

Daniel DG.

J Clin Psychiatry. 2000;61 Suppl 14:49-52. Review.

19.

The expert consensus guideline series. Treatment of behavioral emergencies 2005.

Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP; Expert Consensus Panel for Behavioral Emergencies 2005.

J Psychiatr Pract. 2005 Nov;11 Suppl 1:5-108; quiz 110-2.

PMID:
16319571
20.

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.

Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN.

Schizophr Bull. 2003;29(1):57-72.

Items per page

Supplemental Content

Write to the Help Desk